checkAd

     159  0 Kommentare AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent

    Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio

    Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer platform for generating highly selective small molecule diagnostics

    LAUSANNE, Switzerland, July 28, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today reported new data for its next generation alpha-synuclein positron emission tomography-(PET) tracer during an oral presentation at the Alzheimer’s Association International Conference (AAIC) and anticipates advancing its lead compound toward clinical stage development in Q4 2020.

    The compelling preclinical results demonstrate enhanced contrast and alpha-synuclein target specificity, putting AC Immune’s PET tracer in a strong position to become a first-in-class precision diagnostic tool for Parkinson’s disease (PD). No effective diagnostic agents exist today for PD and other alpha-synucleinopathies, such as multiple system atrophy (MSA), and Lewy Body Dementia (LBD), representing substantial unmet clinical need.

    Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “I am highly encouraged by these results, as they demonstrate AC Immune’s industry-leading expertise in the development of alpha-synuclein-targeting agents. There is increasing recognition of the importance of targeting the right disease pathology at the right time in neurodegenerative diseases, and AC Immune continues to lead the way towards facilitating such an approach through the parallel development of therapeutic and diagnostic agents for important targets such as alpha-synuclein, as well as more well established targets like Tau and Abeta. The data presented at AAIC are a prime example of the power of our Morphomer platform to facilitate the rapid optimization of our PET tracers.”

    Alpha-synuclein misfolding, aggregation and seeding are the molecular basis for the formation of Lewy bodies, a hallmark of PD, MSA, and LBD. The availability of non-invasive diagnostic tools that can distinguish alpha-synucleinopathies from other proteinopathies or normal physiological situations would enable – for the first time – accurate clinical diagnosis, monitoring of disease progression and benefits of drug interventions. ACI-12589 demonstrates significantly increased target occupancy compared to previous-generation candidates as well as a significantly improved signal specificity.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer platform for generating highly selective small molecule …